{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:51:30Z","timestamp":1758959490753},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T00:00:00Z","timestamp":1452902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"INSYS Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00520-015-3056-3","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T19:14:27Z","timestamp":1452885267000},"page":"2669-2675","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain"],"prefix":"10.1007","volume":"24","author":[{"given":"Harold","family":"Minkowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Charles","family":"Brownlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Rauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,16]]},"reference":[{"key":"3056_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","volume":"81","author":"RK Portenoy","year":"1999","unstructured":"Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129\u2013134","journal-title":"Pain"},{"key":"3056_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0269216304pm890oa","volume":"18","author":"A Caraceni","year":"2004","unstructured":"Caraceni A, Martini C, Zecca E et al (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177\u2013183","journal-title":"Palliat Med"},{"key":"3056_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5055\/jom.2010.0009","volume":"6","author":"RK Portenoy","year":"2010","unstructured":"Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6:97\u2013108","journal-title":"J Opioid Manag"},{"key":"3056_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0885-3924(00)00161-5","volume":"20","author":"G Zeppetella","year":"2000","unstructured":"Zeppetella G, O\u2019Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20:87\u201392","journal-title":"J Pain Symptom Manage"},{"key":"3056_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","volume":"47","author":"S Deandrea","year":"2014","unstructured":"Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G (2014) Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage 47:57\u201376","journal-title":"J Pain Symptom Manage"},{"key":"3056_CR6","first-page":"4","volume":"17","author":"G Zeppetella","year":"2010","unstructured":"Zeppetella G (2010) Breakthrough cancer pain (BTcP): from definitions to patient burden. Eur J Palliat Care 17:4\u20137","journal-title":"Eur J Palliat Care"},{"key":"3056_CR7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1089\/jpm.2009.0051","volume":"12","author":"E Prommer","year":"2009","unstructured":"Prommer E (2009) The role of fentanyl in cancer-related pain. J Palliat Med 12:947\u2013954","journal-title":"J Palliat Med"},{"key":"3056_CR8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/ern.11.63","volume":"11","author":"MP Davis","year":"2011","unstructured":"Davis MP (2011) Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 11:1197\u20131216","journal-title":"Expert Rev Neurother"},{"key":"3056_CR9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1185\/03007995.2012.683111","volume":"28","author":"R Rauck","year":"2012","unstructured":"Rauck R, Reynolds L, Geach J et al (2012) Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 28:859\u2013870","journal-title":"Curr Med Res Opin"},{"key":"3056_CR10","unstructured":"Subsys (fentanyl sublingual spray), CII [package insert]. Chandler, AZ: INSYS Therapeutics, Inc (2013)"},{"key":"3056_CR11","first-page":"15","volume":"1","author":"AH Shojaei","year":"1998","unstructured":"Shojaei AH (1998) Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1:15\u201330","journal-title":"J Pharm Pharm Sci"},{"key":"3056_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12","journal-title":"Health Qual Life Outcomes"},{"key":"3056_CR13","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/cncr.24279","volume":"115","author":"SM Weinstein","year":"2009","unstructured":"Weinstein SM, Messina J, Xie F (2009) Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 115:2571\u20132579","journal-title":"Cancer"},{"key":"3056_CR14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1185\/03007995.2010.545380","volume":"27","author":"S Nalamachu","year":"2011","unstructured":"Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J (2011) Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 27:519\u2013530","journal-title":"Curr Med Res Opin"},{"key":"3056_CR15","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","volume":"25","author":"RL Rauck","year":"2009","unstructured":"Rauck RL, Tark M, Reyes E et al (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25:2877\u20132885","journal-title":"Curr Med Res Opin"},{"key":"3056_CR16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0885-3924(01)00306-2","volume":"22","author":"R Payne","year":"2001","unstructured":"Payne R, Coluzzi P, Hart L et al (2001) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 22:575\u2013583","journal-title":"J Pain Symptom Manage"},{"key":"3056_CR17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1185\/03007995.2011.554808","volume":"27","author":"SR Nalamachu","year":"2011","unstructured":"Nalamachu SR, Narayana A, Janka L (2011) Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin 27:751\u2013760","journal-title":"Curr Med Res Opin"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-3056-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3056-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:09:48Z","timestamp":1559081388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-3056-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,16]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3056"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-3056-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,16]]}}}